Herbalife 3rd Quarter 2026 Earnings Conference Call - HERBALIFE LTD

Explicit Guidance:

• Q4 2026 Revenue: Reported net sales growth of 0.5% to 4.5% YoY (including a 200 bps FX headwind); constant currency growth of 2.5% to 6.5% YoY.
• Q4 2026 Adjusted EBITDA: $145 million to $165 million reported; $155 million to $175 million constant currency.
• Q4 2026 CapEx: $13 million to $23 million.
• FY 2026 Revenue: Reported net sales growth of 4.9% to 5.9% YoY; constant currency growth of 5.3% to 6.3% YoY (raised guidance).
• FY 2026 Adjusted EBITDA: $670 million to $690 million reported (maintained); $700 million to $720 million constant currency (raised guidance).
• FY 2026 CapEx: $55 million to $65 million (narrowed range).
• FY 2026 SaaS Costs: Capitalized and prepaid SAS implementation costs of $35 million to $45 million (narrowed range, incremental to CapEx).
• FY 2026 Tax Rate: Expected effective tax rate of approximately 35%.

Business-Segment Outlook:

• Nutrition Clubs: Targeting establishment of a dedicated internal vertical to provide club-specific products, training, and tools; goal to replicate proven practices and unlock productivity across the 64,000+ global clubs (42% of U.S. volume in Q3 2026).
• Technology Ecosystem: Aiming to capture at least 50% of distributors' global consumer transactions within the unified technology ecosystem over the next three years; launch of the common modular platform's first module (24 Games) targeted for Q1 2027, followed by challenges and nutrition club modules.
• Bionic Brand: Expanding in 2027 to include more convenient formats, premium offerings, and additional personalized nutrition SKUs; integrating "Life.io" and "Sports" product lines under the Bionic brand to attract new entrepreneurs and consumers in Q1 2027 and beyond.
• Protocol Platform: Continuing development as one element of a broader, customizable customer engagement platform; future usage and value dependent on distributor adoption of specific DMO modules.
• Product Development: Developing specific nutritional products and programs for consumers using GLP-1 medications; broadening global reach of skincare offerings.

Market and Competitive Outlook:

• Demand Trends: Anticipated continued growth in India as the GST change implemented in Q3 2025 fully rolls through; expectation of sustained volume growth in 2027.
• Pricing & Margins: Fourth quarter adjusted EBITDA margins expected to be lower than Q3 2026; management plans for a "gradual" path to margin expansion in 2027 while monitoring input costs.
• Channel Shifts: Strategy focused on converting digital engagement into measurable transactions to improve retention and growth, leveraging distributor flexibility to customize digital experiences.
• Competitive Advantage: Leveraging the "human connection" and community-based business models (nutrition clubs, fitness events) which the CEO notes provide a distinct advantage against purely digital competitors, particularly as social isolation trends persist.

Macro / Industry Outlook:

• Currency Headwinds: FX expected to remain a headwind to reported net sales and adjusted EBITDA in Q4 2026 (200 bps impact projected); Q3 2026 saw a 160 bps FX headwind.
• Regulatory: No new specific regulatory changes mentioned beyond the previous Q3 2025 GST change in India, which previously accelerated growth.
• Supply Chain: Managing cost changes related to self-manufacturing and sourcing, which contributed to Q3 gross margin pressure, alongside global country mix shifts.

Strategic Initiatives:

• Capital Allocation: Commencing a $250 million share repurchase program in Q4 2026, to be executed systematically and opportunistically; long-term debt target of $1.4 billion total and $1 billion net debt, with a net leverage ratio target of ≤2.0x (achieved 2.0x at Q3 2026).
• Technology Investment: Building a common modular technology foundation to replace disparate apps (Engage, Hub) and reduce reliance on third-party tools; targeting 2027 for full platform rollout.
• Brand Integration: Merging Life.io and Sports offerings into the Bionic brand to create a comprehensive personalized nutrition and performance portfolio.
• Financial Discipline: CFO prioritizing a clear, disciplined approach to margin expansion, with specific three-year margin objectives to be detailed on the Q4 call.

Risks and Headwinds to Outlook:

• FX Volatility: Continued foreign exchange headwinds in Q4 2026 could dampen reported growth rates.
• Input Costs: Potential increases in self-manufacturing and sourcing costs could pressure gross margins in 2027.
• Execution Risk: Strategic success depends on distributor adoption of new technology modules and the ability to effectively scale the nutrition club vertical.
• Product Mix: Unfavorable country mix remains a driver of revenue pressure in certain regions (e.g., EMEA, China).
• Strategic Hedges: Bionic and technology rollout timelines (Q1 2027 start) depend on consumer demand; usage of new apps will determine their ultimate value and the future role of legacy platforms like Protocol.

Management Tone on the Future:

• Confidence Level: High confidence in the company's future, citing "tremendous belief" in the distributor network and entrepreneurial spirit.
• Strategic Pivot: Shift from "reinventing" the business to "leveraging" existing strengths and infrastructure to unlock growth; focus on execution and accountability.
• Change vs. Prior Guidance: Raised FY 2026 revenue and constant currency EBITDA guidance; narrowed CapEx and SaaS cost guidance ranges.
• Leadership Transition: New Interim CEO (John DeSimone) emphasizes ownership, energy, and a commitment to results; CFO (Scott Schaefer) signals a focus on disciplined margin management and capital allocation.

Miscellaneous:

• 24 Games: First event held in Miami with 350+ attendees; target is broader global rollout starting Q1 2027 as a core engagement tool on the new technology platform.
• Cash Flow: YTD operating cash flow of $298 million (up 27% YoY); quarter-end cash position of $409 million.
• Debt: Recent refinancing extended maturity profile with no significant maturities until 2028 convertible notes; net interest expense reduced by $19 million YoY.